These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Immunological characteristics and two novel mutations in TACI in a cohort of 28 pediatric patients with common variable immunodeficiency. Almejún MB; Sajaroff E; Galicchio M; Oleastro M; Bernasconi A; Zelazko M; Danielian S J Clin Immunol; 2012 Feb; 32(1):89-97. PubMed ID: 22076597 [TBL] [Abstract][Full Text] [Related]
28. Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells. Smulski CR; Zhang L; Burek M; Teixidó Rubio A; Briem JS; Sica MP; Sevdali E; Vigolo M; Willen L; Odermatt P; Istanbullu D; Herr S; Cavallari M; Hess H; Rizzi M; Eibel H; Schneider P Cell Rep; 2022 Mar; 38(13):110583. PubMed ID: 35354034 [TBL] [Abstract][Full Text] [Related]
29. TACI deficiency - a complex system out of balance. Salzer U; Grimbacher B Curr Opin Immunol; 2021 Aug; 71():81-88. PubMed ID: 34247095 [TBL] [Abstract][Full Text] [Related]
30. TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. Berglund LJ; Jones GJ; Murali R; Fulcher DA J Allergy Clin Immunol; 2006 Apr; 117(4):870-7. PubMed ID: 16630947 [TBL] [Abstract][Full Text] [Related]
31. Common variable immunodeficiency: two mutations are better than one. La Cava A J Clin Invest; 2013 Oct; 123(10):4142-3. PubMed ID: 24051372 [TBL] [Abstract][Full Text] [Related]
32. The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency. Lee JJ; Jabara HH; Garibyan L; Rauter I; Sannikova T; Dillon SR; Bram R; Geha RS J Allergy Clin Immunol; 2010 Dec; 126(6):1234-41.e2. PubMed ID: 20889194 [TBL] [Abstract][Full Text] [Related]
33. The impact of TACI mutations: from hypogammaglobulinemia in infancy to autoimmunity in adulthood. Barroeta Seijas AB; Graziani S; Cancrini C; Finocchi A; Ferrari S; Miniero R; Conti F; Zuntini R; Chini L; Chiarello P; Bengala M; Rossi P; Moschese V; Di Matteo G Int J Immunopathol Pharmacol; 2012; 25(2):407-14. PubMed ID: 22697072 [TBL] [Abstract][Full Text] [Related]
34. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Poodt AE; Driessen GJ; de Klein A; van Dongen JJ; van der Burg M; de Vries E Clin Exp Immunol; 2009 Apr; 156(1):35-9. PubMed ID: 19210517 [TBL] [Abstract][Full Text] [Related]
37. Effect of TACI signaling on humoral immunity and autoimmune diseases. Zhang Y; Li J; Zhang YM; Zhang XM; Tao J J Immunol Res; 2015; 2015():247426. PubMed ID: 25866827 [TBL] [Abstract][Full Text] [Related]
38. Multi-omics analysis of naïve B cells of patients harboring the C104R mutation in TACI. Ramirez N; Posadas-Cantera S; Langer N; de Oteyza ACG; Proietti M; Keller B; Zhao F; Gernedl V; Pecoraro M; Eibel H; Warnatz K; Ballestar E; Geiger R; Bossen C; Grimbacher B Front Immunol; 2022; 13():938240. PubMed ID: 36072607 [TBL] [Abstract][Full Text] [Related]
39. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Knight AK; Radigan L; Marron T; Langs A; Zhang L; Cunningham-Rundles C Clin Immunol; 2007 Aug; 124(2):182-9. PubMed ID: 17556024 [TBL] [Abstract][Full Text] [Related]
40. Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome. Chinen J; Martinez-Gallo M; Gu W; Cols M; Cerutti A; Radigan L; Zhang L; Potocki L; Withers M; Lupski JR; Cunningham-Rundles C J Allergy Clin Immunol; 2011 Jun; 127(6):1579-86. PubMed ID: 21514638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]